Poster session 11

Programm

• 15:30 – 15:35 3 Min. 2 Min.

  • ePoster
  • P115

  Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience

  • Christopher M. Jensen (New Haven/ US)

   CGRP inhibitors in the clinic, Migraine
• 15:35 – 15:40 3 Min. 2 Min.

  • ePoster
  • P103

  Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial

  • Krisztian Nagy (Budapest/ HU)

   Migraine
• 15:40 – 15:45 3 Min. 2 Min.

  • ePoster
  • P104

  A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine

  • Robert Croop (New Haven/ US)

   CGRP inhibitors in the clinic, Migraine
• 15:45 – 15:50 3 Min. 2 Min.

  • ePoster
  • P105

  Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12- and 52-Week Phase 3 Trials

  • Karen Carr

   Migraine
• 15:50 – 15:55 3 Min. 2 Min.

  • ePoster
  • P106

  Post-hoc Analysis Evaluating Safety of Atogepant in ADVANCE & Open-Label Extension Participants with Cardiovascular Risk Factors

  • Karen Carr

   Migraine
• 15:55 – 16:00 3 Min. 2 Min.

  • ePoster
  • P107

  Cut-off value for Tampa Scale for Kinesiophobia in migraine patients

  • Gabriella Almeida Tolentino (Ribeirão Preto/ BR)

   Migraine, Multidisciplinary clinical assessments
• 16:00 – 16:05 3 Min. 2 Min.

  • ePoster
  • P108

  A retrospective real-life multicenter study on concurrent oral preventives in patients with chronic migraine treated with botulinum toxin

  • Lucas Hendrik Overeem (Berlin/ DE)

   Epidemiology, Migraine
• 16:05 – 16:10 3 Min. 2 Min.

  • ePoster
  • P109

  Impact of Eptinezumab on Patient-Reported Outcomes in Patients With Prior Preventive Treatment Failures

  • Anders Ettrup

   Migraine
• 16:10 – 16:15 3 Min. 2 Min.

  • ePoster
  • P110

  Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial

  • Karen Carr

   Migraine
• 16:15 – 16:20 3 Min. 2 Min.

  • ePoster
  • P111

  Eptinezumab for Migraine Prevention in Patients with 2-4 Prior Treatment Failures: DELIVER Subpopulation Analysis

  • Patricia Pozo-Rosich (Barcelona/ ES)

   Migraine
• 16:20 – 16:25 3 Min. 2 Min.

  • ePoster
  • P112

  Efficacy and Safety of Eptinezumab for Migraine Prevention in Patients With 2–4 Prior Preventive Treatment Failures

  • Patricia Pozo-Rosich (Barcelona/ ES)

   Migraine
• 16:25 – 16:30 3 Min. 2 Min.

  • ePoster
  • P113

  Psychopathological disorders in chronic migraine: is there an association with the endocannabinoid system?

  • Sara Bottiroli (Pavia/ IT)

   Migraine, Multidisciplinary clinical assessments
• 16:30 – 16:35 3 Min. 2 Min.

  • ePoster
  • P114

  Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective Claims Analysis Study

  • Todd Schwedt (Scottsdale/ US)

   Migraine
• 16:35 – 16:40 3 Min. 2 Min.

  • ePoster
  • P116

  Adenosine causes short-lasting vasodilation and headache, but not migraine attacks in migraine patients: A randomized clinical trial

  • Janu Thuraiaiyah (Glostrup/ DK)

   Headache, hormones and dietary, Migraine
• 16:40 – 16:45 3 Min. 2 Min.

  • ePoster
  • P117

  Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial

  • Krisztian Nagy (Budapest/ HU)

   Migraine
• 16:45 – 16:50 3 Min. 2 Min.

  • ePoster
  • P118

  Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: methods and global findings for diagnosis rates and care

  • Manjit Matharu (London/ GB)

   Migraine
• 16:50 – 16:55 3 Min. 2 Min.

  • ePoster
  • P119

  Eptinezumab Improved Work Productivity in Adults With Migraine and Prior Preventive Treatment Failures: Results From the Randomized, Double-Blind, Placebo-Controlled DELIVER Study

  • Anders Ettrup

   Migraine
• 16:55 – 17:00 3 Min. 2 Min.

  • ePoster
  • P120

  Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis

  • Karen Carr

   Migraine